Real-world experience and long-term outcomes of a mandatory non-medical switch of adalimumab originator to biosimilars in inflammatory bowel disease

Figure 1 Patient selection.

Figure 2 Treatment persistence. A: Kaplan-Meier survival analysis does not demonstrate any statistically significant difference in treatment persistence by 30-months of patients who remain on the originator vs those who underwent the biosimilar switch (log-rank P value = 0.543). Seven discontinuations (16.3%) occurred in the originator group, compared to 27 (11.8%) in the biosimilars group. Specific reasons for treatment discontinuations are summarized in Table 2; B: Pair-wise Kaplan-Meier survival analysis of all five biosimilars to the adalimumab originator did not show any difference in treatment persistence by 30-months post-switch. Log-rank P values are displayed above. Specific reasons for treatment discontinuation are summarized in Table 3.

Figure 3 Adverse outcomes. A: No statistically significant differences were observed in rates of adverse outcomes (regardless of subsequent treatment discontinuations) were observed between originator and biosimilar cohorts (P = 0.206); B: Rates of adverse outcomes subdivided amongst each biosimilar compared to the originator control group. N-values are indicated within bars.